Volatile organic compound

New Regulations May Be Coming To Combat Dangerous “Forever Chemicals” – This Cleantech Innovator Is Ready

Retrieved on: 
Jeudi, février 22, 2024

BioLargo is a cleantech and life sciences innovator and engineering services solution provider.

Key Points: 
  • BioLargo is a cleantech and life sciences innovator and engineering services solution provider.
  • Watch the full interview here: https://www.youtube.com/live/HD8NhCSUz9w?si=kY8_GOr8j17UFX4h
    This post contains sponsored content.
  • This content is for informational purposes only and is not intended to be investing advice.
  • Benzinga received 32,000 USD from BioLargo in consideration for the publication of this content.

Alen Air Purifiers are Transforming Home Health to Fight Rising Indoor Air Quality Dangers

Retrieved on: 
Jeudi, mars 7, 2024

The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.

Key Points: 
  • The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.
  • “The dangers of poor indoor air quality are not just invisible – they silently jeopardize our health, amplifying the risk of respiratory issues, allergies and long-term health complications,” said Alen CEO, Warburg Lee.
  • Alen air purifiers with HEPA fresh filtration capture fine particles, including ash, soot and VOCs, effectively removing them from the indoor air and reducing exposure to harmful pollutants and allergens like pollen, pet dander, and mold spores, providing symptom relief and improving overall indoor air quality.
  • Addressing these sources of indoor air pollution typically involves implementing strategies such as improving ventilation, using air purifiers with HEPA filters like Alen, and reducing or eliminating the use of products with harmful chemicals.

Synexis® LLC. Introduces Sentry XL, Expanding Indoor Environmental Quality Solutions

Retrieved on: 
Mercredi, mars 6, 2024

LENEXA, Kan., March 6, 2024 /PRNewswire/ -- Synexis is excited to introduce the Sentry XL, our latest product designed to offer exceptional performance and expanded coverage, transforming the way we experience living and working in larger occupied spaces.

Key Points: 
  • The Sentry XL joins the Synexis portfolio of Indoor Environmental Quality (IEQ) devices using a patented and advanced technology to continuously combat harmful pathogens in the air and on surfaces.
  • "We are excited to introduce the Sentry XL as the latest addition to our expanding product portfolio.
  • Key Features of the Sentry XL:
    Maximum Coverage: Effectively safeguards indoor areas of up to 3,000 square feet.
  • Robust Design: Crafted from high-quality materials, the Sentry XL is housed in a stainless-steel and aluminum frame, ensuring durability and reliability in challenging indoor conditions.

ARKEMA will be attending this year's JEC edition with A unique portfolio of materials for Composites STAND 5T40 - HALL 5

Retrieved on: 
Jeudi, février 29, 2024

PI films are used in various industries, including smart devices, electric vehicles, semiconductors, displays, aerospace, and industrial applications.

Key Points: 
  • PI films are used in various industries, including smart devices, electric vehicles, semiconductors, displays, aerospace, and industrial applications.
  • UNLEASHING THE FUTURE WITH ARKEMA'S UDX® TAPES - Arkema is proud to present a range of semi-finished composite products under the UDX® brand.
  • Building on its unique set of expertise in materials science, Arkema offers a portfolio of first-class technologies to address ever-growing demand for new and sustainable materials.
  • The Group reported sales of around € 11.5 billion in 2022, and operates in some 55 countries with 21,100 employees worldwide.

ARKEMA will be attending this year's JEC edition with A unique portfolio of materials for Composites STAND 5T40 - HALL 5

Retrieved on: 
Jeudi, février 29, 2024

PI films are used in various industries, including smart devices, electric vehicles, semiconductors, displays, aerospace, and industrial applications.

Key Points: 
  • PI films are used in various industries, including smart devices, electric vehicles, semiconductors, displays, aerospace, and industrial applications.
  • UNLEASHING THE FUTURE WITH ARKEMA'S UDX® TAPES - Arkema is proud to present a range of semi-finished composite products under the UDX® brand.
  • Building on its unique set of expertise in materials science, Arkema offers a portfolio of first-class technologies to address ever-growing demand for new and sustainable materials.
  • The Group reported sales of around € 11.5 billion in 2022, and operates in some 55 countries with 21,100 employees worldwide.

Wandering Oaks' Residence wins One-of-a-Kind Custom Home Award

Retrieved on: 
Jeudi, février 29, 2024

ASHEVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Red Tree Builders, Inc., based in Asheville, NC, proudly announces that their 'Wandering Oaks' residence has clinched an award in the One-of-a-Kind Custom Home 3,001 - 4,000 sq.

Key Points: 
  • ASHEVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Red Tree Builders, Inc., based in Asheville, NC, proudly announces that their 'Wandering Oaks' residence has clinched an award in the One-of-a-Kind Custom Home 3,001 - 4,000 sq.
  • ft category at the 2023 Best in American Living™ Awards (BALA), presented by the National Association of Home Builders (NAHB).
  • The 3,990 square foot home was designed by architect Wilson Architects, Inc. of Asheville and landscape architect Jerald A.
  • With material selections prioritizing aesthetics, performance, and sustainability, Wandering Oaks promises lasting beauty and minimal maintenance for years to come.

Government of Canada announces draft rules to cut pollutants that cause smog in communities across Canada

Retrieved on: 
Vendredi, février 23, 2024

Today, Environment and Climate Change Canada and Health Canada announced the draft regulations to further reduce emissions from the petroleum sector of harmful volatile organic compounds (VOCs), which are airborne pollutants that contribute to smog.

Key Points: 
  • Today, Environment and Climate Change Canada and Health Canada announced the draft regulations to further reduce emissions from the petroleum sector of harmful volatile organic compounds (VOCs), which are airborne pollutants that contribute to smog.
  • These changes would improve air quality in neighbourhoods and communities across the country that are close to oil and gas facilities.
  • The draft regulations reflect an on-going commitment to environmental justice and the need to address disproportionate environmental harms on communities near industrial sites.
  • Exposure levels are higher in communities near large emission sources, including Indigenous and low-income communities already facing increased health burdens.

Chrysler Halcyon Concept Pushes Innovative Boundaries, Offers Forward-looking Vision of Brand's All-electric Future

Retrieved on: 
Mardi, février 13, 2024

"The Chrysler Halcyon Concept creates a level of serenity that fully represents the Halcyon name.

Key Points: 
  • "The Chrysler Halcyon Concept creates a level of serenity that fully represents the Halcyon name.
  • The Chrysler Halcyon Concept is the latest in a steady progression of futuristic concepts representing the brand's electrification transformation.
  • Previously, the brand revealed the Chrysler Portal Concept in 2017, the Chrysler Airflow Concept in 2022 and the Chrysler Synthesis Cockpit Demonstrator in 2023.
  • The Chrysler Halcyon Concept, designed on the STLA Large platform, offers an aerodynamic, streamlined and uncompromising vision of the Chrysler brand's future exterior character.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Retrieved on: 
Mardi, février 13, 2024

ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.

Key Points: 
  • “The approval by the European Commission is yet another important regulatory milestone underscoring the potentially transformative benefit of CASGEVY for patients with severe sickle cell disease and transfusion-dependent beta thalassemia,” said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics.
  • Vertex is working closely with national health authorities in the European Union (EU) to secure access for eligible patients as quickly as possible.
  • Through this work, they have secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • There are currently three activated ATCs in the EU with plans to activate a total of approximately 25 centers across Europe.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Retrieved on: 
Mardi, février 13, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.
  • CASGEVY is the only genetic therapy approved for SCD and TDT patients in the European Union (EU) and with this approval, there are now more than 8,000 patients potentially eligible for treatment.
  • Through this work, Vertex has secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • Vertex continues to engage with hospitals experienced in stem cell transplantation to establish a network of independently operated authorized treatment centers (ATCs) for the administration of CASGEVY.